Medical insurance price of dasatinib in 2024

Dasatinib (Dasatinib), a drug that has excellent performance in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), has been launched in China and has been successfully included in medical insurance. This move is undoubtedly a great benefit for patients who need to take this drug for a long time. However, even if it is included in medical insurance, its price and reimbursement policy are still the focus of attention of patients.

Currently, the common specifications of dasatinib are50mg*60 tablets and 20mg*60 tablets per box, and the price is about RMB 10,000. However, it should be noted that this is only the original price of the drug, and the actual price paid will be affected by medical insurance reimbursement. Medical insurance policies vary in different regions, so reimbursement rates will also vary. This means that when patients purchase dasatinib, the actual price they pay may vary from region to region. Patients should consult their local medical insurance bureau or hospital.

The reason why dasatinib is able to exert such significant efficacy is mainly due to its active substancedasatinib. This substance blocks the BcrAbl protein kinase produced by leukemia cells, thereby inhibiting the uncontrolled reproduction of these cells. At the same time, it can also block other kinases and further reduce the number of leukemia cells.

Although the price of dasatinib is already relatively high in China, the price of its original drug is even more expensive in overseas markets. However, for patients looking for more affordable options, there are some generic options available in overseas markets. These generic drugs are basically the same as the original drugs in terms of ingredients, but are much cheaper. For example, the price of a generic dasatinib of the same specification produced by an Indian pharmaceutical factory may be only a few hundred yuan (the price may fluctuate due to exchange rates).